(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
CA 2087606 C · Owner: Allergan, Inc. · Inventors: Gluchowski, Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound selected from the group consisting of those having the formula:, (see formula I) and pharmaceutically acceptable acid addition salts thereof, wherein R1 and R4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R2s are each H or alkyl radicals having 1 to 4 carbon atoms or are together, oxo; the R3s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo, provided that the R2s or the R3s are alkyl radicals; the 2-imidazolin-2ylamino group may be in any of the 5-, 6 7- or 8-, positions of the quinoxaline nucleus; and R5 R6 and R7, each is located in one of the remaining 5- 6-, 7- or, 8- positions of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 22, 1991 and granted October 23, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 22, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 22, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.